Jhaveri Shailesh, Upashani Tejas, Bhadauria Jitendra, Biswas Swati, Patel Kamlesh
Consultant, Department of Orthopedics, Jaslok Hospital & Research Centre , Mumbai, India .
Consultant, Department of Orthopedics, Fortis Hospital , Mumbai, India .
J Clin Diagn Res. 2015 Oct;9(10):RC04-8. doi: 10.7860/JCDR/2015/13000.6635. Epub 2015 Oct 1.
Various osteoporosis guidelines are available for practice.
To understand the current clinical practice scenario from the perspective of Indian orthopaedicians, especially about the epidemiology, clinical manifestations, approach to diagnosis and management and patient compliance patterns to long term treatment.
A pre-validated structured questionnaire containing questions (mostly objective, some open-ended) catering to various objectives of the study was circulated amongst orthopaedic surgeons across India by means of post/courier, after giving a brief overview of the study telephonically. Data was extracted from the completed questionnaires, and analysed using Microsoft Excel software.
The questionnaire was filled by a total of 84 orthopaedicians throughout India. The prevalence of osteoporosis in India according to the orthopaedic surgeons was 38.4% and there was a female preponderance. Most of the respondents felt out of every 100 osteoporosis patients in India, less than 20 patients are actually diagnosed and treated for osteoporosis. The most common initial presenting feature of established osteoporosis cases was general symptoms. Most respondents preferred Dual-energy X-ray absorptiometry (DEXA) as the initial investigation for the diagnosis of osteoporosis in a patient presenting with typical features. While most respondents preferred once-a-month oral over intravenous (IV) bisphosphonates, they agreed that IV administration had advantages such as lower gastrointestinal side effects and improved compliance. The average duration of therapy of oral bisphosphonates was the longest (27.04 months) among the other anti- osteoporosis therapies that they used. On an average, the patient compliance rate in osteoporosis management was around 64%. IV Zoledronic acid (ZA) and intranasal calcitonin were infrequently used than other anti- osteoporosis therapies. While concerns about cost and availability deterred more frequent usage, there was an agreement that if used regularly these two agents may improve compliance rates among patients.
Current clinical practice scenario of osteoporosis management in India largely adheres to various clinical practice guidelines for osteoporosis. Side effects and lengthy duration of therapy with bisphosphonates seem to be the main factors leading to a low patient compliance. Widespread popularization of once-yearly Zoledronic acid and intranasal calcitonin spray may improve patient compliance and reduce side effect incidence.
有各种骨质疏松症指南可供临床实践参考。
从印度骨科医生的角度了解当前的临床实践情况,特别是关于骨质疏松症的流行病学、临床表现、诊断和管理方法以及患者对长期治疗的依从模式。
在通过电话简要介绍研究概况后,通过邮寄/快递向印度各地的骨科医生发放一份预先验证的结构化问卷,问卷包含针对研究各项内容的问题(大多为客观题,部分为开放式问题)。从填写完整的问卷中提取数据,并使用微软Excel软件进行分析。
印度各地共有84名骨科医生填写了问卷。根据骨科医生的看法,印度骨质疏松症的患病率为38.4%,女性占多数。大多数受访者认为,在印度每100名骨质疏松症患者中,实际被诊断和治疗的患者不到20例。已确诊的骨质疏松症病例最常见的初始表现特征是全身症状。大多数受访者倾向于将双能X线吸收法(DEXA)作为对具有典型特征患者进行骨质疏松症诊断的初始检查方法。虽然大多数受访者更倾向于每月口服一次双膦酸盐而非静脉注射(IV)双膦酸盐,但他们也认同静脉注射有诸如胃肠道副作用较低和依从性提高等优点。在他们使用的其他抗骨质疏松症治疗方法中,口服双膦酸盐的平均治疗持续时间最长(27.04个月)。平均而言,骨质疏松症管理中的患者依从率约为64%。与其他抗骨质疏松症治疗方法相比,静脉注射唑来膦酸(ZA)和鼻用降钙素的使用频率较低。虽然对成本和可及性的担忧阻碍了它们更频繁地使用,但大家一致认为,如果定期使用这两种药物,可能会提高患者的依从率。
印度目前骨质疏松症管理的临床实践情况在很大程度上遵循各种骨质疏松症临床实践指南。双膦酸盐治疗的副作用和疗程较长似乎是导致患者依从性低的主要因素。每年一次的唑来膦酸和鼻用降钙素喷雾剂的广泛普及可能会提高患者依从性并降低副作用发生率。